Open AccessFecal Microbiota Transplantation: An Ambiguous Translational Pathway for a Promising Treatment
Author(s) -
Joseph Josiane,
Saha Srishti,
GreenbergWorisek Alexandra J.
Publication year - 2019
Publication title -
clinical and translational science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.303
H-Index - 44
eISSN - 1752-8062
pISSN - 1752-8054
DOI - 10.1111/cts.12621
Subject(s) - clostridium difficile , medicine , toxic megacolon , colitis , clostridium difficile colitis , diarrhea , antibiotics , leukocytosis , inflammatory bowel disease , disease , gut flora , intensive care medicine , transplantation , enterocolitis , ulcerative colitis , immunology , microbiology and biotechnology , biology
Clostridium difficile is a common nosocomial pathogen that can cause debilitating and fatal diarrheal illness. Patients diagnosed with C. difficile colitis are typically treated with broad spectrum antibiotics but frequently experience recurrences despite appropriate therapy. Another therapeutic modality, fecal microbiota transplantation (FMT), effectively resolves disease for many of these patients; however, issues related to lack of information and standardization have prevented FMT regulation and complete translation to the clinic.